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inTroDUcTion
Intratumoral genetic heterogeneity in renal cell carcinoma 
(RCC) has provided important insights into the evolu-
tionary pathway of RCC tumorigenesis.1 However, routine 
analysis of genetic intratumoral heterogeneity has yet to 
translate usefully into clinical practice as it requires special-
ized multiregional tumor sampling, complex computa-
tional analysis and sequencing platforms.
Metabolic reprogramming is a feature common to many 
solid tumors. Increased glucose uptake, glycolysis and 
reduced oxidative phosphorylation, known as the Warburg 
effect,2 have been reported in RCC.3 Hyperpolarized 
carbon-13 (13C) MRI (HP-MRI) is a novel non-ionizing 
imaging technique that allows non-invasive real-time anal-
ysis of metabolic pathways in vivo.4 Hyperpolarization 
using dissolution-dynamic nuclear polarization (DNP) 
technology provides unprecedented sensitivity for the 
detection of metabolism of 13C-labeled substrates such 
as pyruvate, fumarate and glucose in vivo.4 For example, 
following administration of 1-[13C] pyruvate, a number of 
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aBSTracT:
Intratumoral genetic heterogeneity and the role of metabolic reprogramming in renal cell carcinoma have been exten-
sively documented. However, the distribution of these metabolic changes within the tissue has not been explored. We 
report on the first-in-human in vivo non-invasive metabolic interrogation of renal cell carcinoma using hyperpolarized 
carbon-13 (13C) MRI and describe the validation of in vivo lactate metabolic heterogeneity against multi regional ex vivo 
mass spectrometry. hyperpolarized carbon-13 (13C)-MRI provides an in vivo assessment of metabolism and provides a 
novel opportunity to safely and non-invasively assess cancer heterogeneity.
2 of 5 birpublications.org/bjrcr BJR Case Rep;5:20190003
BJR|case reports  Tran et al
via the reaction catalyzed by lactate dehydrogenase (LDH). 
This technique has recently been successfully translated into the 
clinical domain and is a promising tool for disease characteriza-
tion and therapeutic response monitoring in prostate and brain 
tumors.5–8
Here, we report on the first-in-human non-invasive metabolic 
interrogation of RCC using HP-MRI and describe the validation 
of in vivo lactate metabolic heterogeneity imaged using HP-MRI 
against multiregional ex vivo mass spectrometry.
MeThoDS anD MaTerialS
A 72-year-old female with a history of a previous right radical 
nephrectomy (17 years earlier) for clear cell RCC had an inci-
dental finding of a 6.8 × 5.1 × 6.1 cm mass on the left kidney 
(Figure 1) confirmed as clear cell RCC.
Histopathological analysis of laparoscopic radical nephrectomy 
specimen confirmed ISUP/WHO Grade two clear cell RCC 
(staging pT3a).
The patient provided written informed consent for HP-MRI 
(Research Ethics Committee (REC) reference number 17/
LO/0431) ( ClinicalTrials. gov Identifier: NCT03687645 ) and for 
tissue based assays (REC reference number 16/WS/0039).
Production of hyperpolarized 1-[13C] pyruvate
Hyperpolarized 1-[13C] pyruvate solution was filled and assem-
bled under aseptic conditions then produced using a DNP 
polarizer (SPINlab, GE Healthcare, Milwaukee, Wisconsin) 
and a sterilized fluid path.9 The filled sterilized fluid path was 
loaded into the hyperpolarizer and the sample, consisting of 1.47 
g 1-[13C] pyruvic acid (GMP Precursor from Sigma Aldrich, 
Vienna, Austria) doped with 15 mM AH111501 electron para-
magnetic agent, underwent microwave irradiation for approxi-
mately 2 h to achieve a polarization of 31.9%. The sample was 
then dissolved in 38 ml of sterile water and neutralized with 17.5 
g sterile trometamol buffer solution (333 mM Tris and 600 mM 
NaOH) in 19 ml of sterile water. Release criteria for sterile hyper-
polarized solution for injection are tabulated in Table 1.
Imaging set-up
The patient was positioned in a clinical 3 T integrated PET-MR 
scanner (Siemens Biograph mMR, Enlargen, Germany) in the 
supine position with an intravenous (i.v.) catheter placed in the 
left arm. A specialized custom-design clamshell 13C transmit coil 
was used with two (anterior and posterior) 7-channel 1H/13C 
receive surface phase array coils (RAPID Biomedical GmbH, 
Rimpar, Germany) for signal excitation and reception of 13C 
signals respectively.
The i.v. line was connected to an automatic dual chamber power 
injector with the first chamber (chamber A) programmed to 
deliver hyperpolarized 1-[13C] pyruvate solution at a rate of 5 
ml s−1. The second chamber (chamber B) was pre-loaded and 
programmed to deliver 20 ml of normal saline flush immediately 
after hyperpolarized solution injection.
Anatomical localization of the renal tumor was performed 
on axial and coronal T2 weighted imaging. A turbo spin echo 
sequence was utilized with the following parameters: repetition 
time = 5400 ms, effective echo time = 111 ms, slice thickness = 
3 mm, number of slices = 30, Field of view (axial) = 203 mm x 
460 mm, field of view (coronal) = 369 mm x 460 mm, echo train 
length = 15, number of signal averaging = 1.
Following localization of the tumor, a central axial imaging slice 
was planned under the direction of a board certified radiologist 
for subsequent 13C imaging.
Hyperpolarized MRI
40 ml of hyperpolarized 1-[13C] pyruvate was injected at a rate 
of 5 ml s−1 followed by a flush of 20 ml of normal saline at 3 ml 
s−1. Repeated 13C chemical shift imaging (CSI) measurements 
were performed (repetition time = 80 ms, time of echo = 3 ms, 
flip angle = 10°, bandwidth = 10,000 Hz, field of view = 120 mm 
x 120 mm, slice thickness = 30 mm, acquisition matrix = 16 × 
Figure 1. Contrast-enhanced CT of the abdomen at the level 
of left kidney. (a) Coronal and (b) axial slices showing an inci-
dental finding of a 6.8 × 5.1 × 6.1 cm mass in the left kidney 
(arrows). There were no radiological signs of metastatic 
disease on CT of chest, abdomen and pelvis.
Table 1. Release criteria for final product
Release criteria for sterile hyperpolarized solution in 
Medrad syringe for injection
Appearance Clear colorless solution with a slightly 
green tinge and free from visible particles
Validations satisfactory 
for
Sterility: Complies with Ph. Eur. 
Endotoxins: Complies with Ph.Eur.
Physical & chemical 
parameters
Based on UCSF Limits
13C nuclear polarization Not Less Than 10.0%a
Pyruvate 220–280 mM
Residual AH111501 Not more than 3.0 µM
pH (i) QC module
(ii)pH strips






25.0 – 37.0o Cb
Drug product volume >38 ml
Compliance with TSE regulations
TSE, transmissible spongiform encephalopathies.
aPolarization at the start of dissolution. UCSF limit NLT 15%
bTemperature at the time of analysis
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16), commencing at a delay of 25 s following start of injection 
to allow for sufficient hyperpolarized solution delivery to the 
kidney. Single-slice CSI images were acquired every 20 s for a 
total of 12 repetitions.
The CSI data were analyzed offline (MATLAB 2016; MathWorks 
Inc., Natick, MA). The individual free induction decays across 
the CSI grid were apodized with an exponential 10 Hz filter in 
the time domain and then Fourier transformed. The areas of 
spectral peaks were calculated to produce the metabolic maps. 
Metabolic maps of the 1-[13C] labeled lactate and pyruvate spec-
tral areas and lactate/pyruvate ratio were generated for the first 
acquired CSI dataset (demonstrating the highest formation of 
1-[13C] lactate). The 1-[13C] lactate signal was not measurable on 
subsequent CSI data.
Tissue handling
After macroscopic pathology review, multiregional tissue samples 
were collected within 30 min of nephrectomy. A 1 cm thick 
axial slice of kidney was selected at the level of the renal hilum 
(visually matched to the MRI CSI imaging slice) and regional 
sampling was labelled sequentially (10 samples of tumor, and 5 
samples of adjacent non-tumorous kidney tissue). Samples were 
placed in cryo-vials and immediately snap frozen with liquid 
nitrogen. Samples were formalin fixed, processed in paraffin and 
stained with hematoxylin & eosin after sectioning for micro-
scopic confirmation of presence or absence of malignancy.
Lactate measurement by liquid chromatography-
mass spectrometry
Frozen tissue samples were weighed into Precellys tubes prefilled 
with ceramic beads (Stretton Scientific Ltd., Derbyshire, UK), 
and an exact volume of extraction solution (30% acetonitrile, 
50% methanol and 20% water) was added to obtain 40 mg spec-
imen per mL of extraction solution. Samples were lyzed using 
a Precellys®24 tissue homogeniser (Bertin Corp, Rockville, MD. 
5500 rpm 15 s x 2) and then centrifuged (16,162 x g for 10 min 
at 4°C). The supernatant was transferred to glass vials (Microsolv 
Technology Corp., Leland, NC) and stored at −80°C until LC-MS 
analysis.
Samples were randomized in order to avoid bias due to machine 
drift and the operator was blind to the HP-MRI assessment. 
LC-MS analyses were performed on a Q Exactive mass spec-
trometer (Thermo Fisher Scientific) mass spectrometer coupled 
to an Ultimate 3000 RSLC system (Dionex). The liquid chroma-
tography system was fitted a ZIC-pHILIC column (150 × 2.1 
mm) and respective guard (20 × 2.1 mm) (all Merck Millipore, 
Germany), and metabolites were eluted with the previously 
described gradient.10 The mass spectrometer was operated in 
full MS and polarity switching mode. The acquired spectra were 
analyzed using XCalibur Quan Browser software (Thermo Fisher 
Scientific). Absolute quantification of lactate was performed by 
interpolation of the corresponding standard curve obtained 
from serial dilutions of a commercially available standard 
(Sigma Aldrich, Vienna, Austria) running with the same batch 
of samples.
reSUlTS
1-[13C] Lactate signal was observed on the first, and 1-[13C] 
pyruvate signal on the first and second acquisition of the CSI 
temporal series.
The 1-[13C] pyruvate signal (Figure  2d) provides a measure of 
blood flow, whilst the 1-[13C] lactate signal demonstrates metab-
olism (Figure 2e).9
Heterogeneous 1-[13C] pyruvate signal was seen across the RCC, 
reflective of variability of blood flow (Figure 2d). Heterogeneous 
formation of 1-[13C] lactate is also evident (Figure 2e). Moreover, 
areas of high 1-[13C] lactate formation did not always conform 
to areas of high blood flow as highlighted by the lactate/pyruvate 
ratio map (Figure 2f).
LC-MS analysis confirmed heterogeneous lactate levels within 
tumor samples (Figure 2b, samples 1–10), as depicted on the bar 
chart in Figure 3. The highest level of lactate by mass spectrom-
etry (Figure 3—red bar) was found in region 5, corresponding 
to the region displaying the highest 1-[13C] lactate signal in the 
HP-MRI scan (Figure  2—red arrow). Further 1-[13C] lactate 
formation was observed at imaging corresponding to samples 
8–9 (Figure 3a—orange bars) and sample 1 (Figure 3a—yellow 
bar).
Overall, we observed heterogeneity of HP-MRI 1-[13C] lactate 
signal generally conforming to the heterogeneity found at mass 
spectrometry metabolic analysis.
Figure 2. (a) Axial T2 weighted turbo spin echo MRI through 
kidney. Renal tumor (arrows) and normal-appearing renal 
tissue (arrow head) are shown. (b) 1 cm thick axial slice of 
kidney at the level of the renal hilum and 15 tissue samples 
(1–10 tumor samples and 11–15 non-tumor samples). Images 
from 13C CSI first acquisition (c–f). (c) Corresponding spectra 
of the arrowed region on (b) (region 5). The spectrum shows 
prominent signals from lactate (left) and pyruvate (right). (d) 
Interpolated hyperpolarized 1-[13C] pyruvate map overlaid 
on T2 weighted turbo spin echo MRI. (e) Interpolated hyper-
polarized 1-[13C] lactate map overlaid on T2 weighted turbo 
spin echo MRI. (f) Interpolated hyperpolarized 1-[13C] lactate/
pyruvate map overlaid on T2 weighted turbo spin echo MRI. 
Bottom row depicts intratumoral heterogeneity of; pyruvate 
delivery (d), pyruvate to lactate metabolic conversion (e) and 
the ratio of lactate to pyruvate map (f) (a.u.). CSI, chemical 
shift imaging.
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DiScUSSion anD conclUSion
In this study, we report on the first-in-human in vivo non-in-
vasive metabolic assessment of RCC using 1-[13C] pyruvate 
HP-MRI and validate the results with ex vivo multi regional 
LC-MS analysis.
HP-MRI using dissolution DNP produces a dramatic signal 
enhancement, allowing real-time imaging of metabolic path-
ways.4 Until now, the clinical application of HP-MRI in 
malignancies has been limited to prostate cancer5,6 and brain 
tumors.7,8 To the best of our knowledge this study represents 
two novel factors: it is the first-in-human 1-[13C] pyruvate 
HP-MRI study in RCC, and it is the first HP-MRI study with 
tissue assay validation.
Unlike the multiregional sampling used for tissue-based assess-
ment of genetic and metabolic heterogeneity, HP-MRI provides 
a non-invasive technique that can be repeated over time and thus 
could be used for longitudinal tumor monitoring.6
It has been previously shown that the pyruvate signal build-up 
precedes the lactate signal build-up in the time course data 
of pre-clinical animal models, consistent with the notion that 
the pyruvate signal reflects its delivery to the tissue and cells 
whilst the lactate signal reflects pyruvate-to-lactate conversion 
catalyzed by lactate dehydrogenase in the glycolytic pathway.11
In our patient, the regional distribution of pyruvate and lactate 
differed markedly across the RCC, suggesting that blood flow 
and metabolism were not integrally linked within the cancer.
One possible explanation for our observation is that higher 
levels of LDH are found in areas of tumor which exhibit 
hypoxia.12 Tumor hypoxia can be caused by high levels of 
metabolic activity or through relative decrease in effective 
blood flow.13 Hence low 1-[13C] pyruvate signal, reflecting 
limited blood flow, may occur together with high 1-[13C] 
lactate signal, reflecting increased metabolic activity.
We also observed heterogeneity of in vivo 1-[13C] lactate 
signal across the tumor confirmed by ex vivo mass spec-
trometry. Genomic, microstructural and macrostruc-
tural heterogeneity has been noted in cancers including 
RCC.1,14,15 Our results confirm heterogeneous metabolic 
activity is also present within RCC. Future work linking 
genomic, metabolic, microstructural and macrostructural 
changes is needed to explore if RCC metabolic heterogeneity 
relates to genomic heterogeneity; and, whether metabolic 
heterogeneity is a result of micro/macrostructural hetero-
geneity or conversely results in RCC micro/macrostructural 
heterogeneity.
The CSI sequence used within this study enabled single slice 
imaging with limited temporal resolution. New sequences are 
being developed for hyperpolarized 13C metabolic imaging 
allowing full anatomical coverage and improved temporal 
resolution.16–18
HP-MRI has a variety of potential clinical applications. For 
example, knowledge of RCC metabolic activity may provide 
a prognostic tool to help treatment stratification, such as 
whether active surveillance or urgent surgery is warranted. 
Temporal changes in metabolism could be used to monitor 
patients on active surveillance, and to provide an assessment 
of treatment response. Indeed, identifying areas of higher 
metabolic activity within solid tumors in general could help 
guide target biopsy and themselves act as targets for novel focal 
therapies.
Learning points
1. Metabolic reprogramming is a feature common to many 
solid tumors with increased glucose uptake, glycolysis 
and reduced oxidative phosphorylation (Warburg effect) 
reported in RCC
2. Hyperpolarized carbon-13 (13C) MRI is a novel non-
ionizing imaging technique that allows non-invasive real-
time analysis of metabolic pathways in vivo.
3. We report on the first-in-human in vivo non-invasive 
metabolic assessment of RCC using 1-[13C] pyruvate HP-
MRI and validate the results with ex vivo multiregional 
liquid chromatography–mass spectrometry analysis.
4. The regional distribution of pyruvate and lactate differed 
markedly across the RCC, suggesting that blood flow and 
metabolism were not integrally linked within the cancer
5. Knowledge of RCC metabolic activity using hyperpolarized 
carbon-13 (13C) MRI may provide a future prognostic tool 
to help treatment stratification.
Figure 3. (a) Bar chart of liquid chromatography–mass spec-
trometry analysis. The graph depicts liquid chromatography–
mass spectrometry analysis of the multiregional samples 
from the tumor. The highest level of lactate accumulation was 
found in region 5 (red bar) in consistence with the findings 
of hyperpolarized 1-[13C] lactate map (Figure 2e, red arrow). 
Colored bars correspond to colored circles in Figure 2b. (b) 
Box and whisker plot of liquid chromatography–mass spec-
trometry analysis of the multiregional samples from tumor 
and non-tumor areas. The median and interquartile range 
of the weight of lactate per sampled area was 3.7 μg/mg of 
tissue wet weight and 0.89 for tumor samples and 2.4 μg/mg 
of tissue wet weight and 0.18 for non-tumor samples respec-
tively (p = 0.002). The boundaries of the box show 25th and 
75th percentiles, and the line within the box is the median. 
Whiskers show 10th and 90th percentiles.
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